Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. · ¶23
We granted certiorari, 607 U. S. 1147 (2026), to decide whether Hikma’s various statements, when considered in their totality, boost Amarin’s lawsuit over the Rule 12(b)(6) hurdle. For the reasons that follow, we hold that they do not.Read in context ›
slip opinion
Source edition
Passage preview. Read in context for the complete text, notes and references.